TCGA-XF-A9T0-01A-11R-A39I-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 26.24835742
- os_event
- false
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.540
- UNFOLDED_PROTEIN_RESPONSE+0.380
- MYC_TARGETS_V1+0.360
- DNA_REPAIR+0.340
- OXIDATIVE_PHOSPHORYLATION+0.260
- ANGIOGENESIS+0.240
- E2F_TARGETS+0.210
- MTORC1_SIGNALING+0.210
- PROTEIN_SECRETION+0.190
- ADIPOGENESIS+0.110
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.700
- INTERFERON_GAMMA_RESPONSE-0.510
- TNFA_SIGNALING_VIA_NFKB-0.320
- COMPLEMENT-0.310
- INFLAMMATORY_RESPONSE-0.300
- KRAS_SIGNALING_DN-0.280
- ESTROGEN_RESPONSE_LATE-0.260
- COAGULATION-0.250
- HEDGEHOG_SIGNALING-0.250
- IL6_JAK_STAT3_SIGNALING-0.250
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C3N-03076 | — | cohortMD1 | 0.843 |
| 2 | X0c9d8dde.aec7.4a95.b86c.da554465897b | — | cohortSQ1 | 0.833 |
| 3 | MNG332 | — | — | 0.831 |
| 4 | SRR8518345 | — | E | 0.831 |
| 5 | 9ca1da07-df79-4bbf-be81-0ef9de95ab0c | — | — | 0.828 |
| 6 | ERR2278885 | — | — | 0.824 |
| 7 | C3N-02290 | — | cohortA4 | 0.821 |
| 8 | SRR6013505 | — | cohortA4 | 0.820 |
| 9 | 176e93be-1ae5-43f2-a0b5-17f31695e679 | — | — | 0.820 |
| 10 | TCGA-UF-A71A-06A-11R-A39I-07 | — | — | 0.817 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.540 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.380 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.360 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.340 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.260 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.240 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.210 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.210 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.190 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.110 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.110 | Inavolisib | — uncovered |
| HYPOXIA | 0.100 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.030 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.030 | Inavolisib | — uncovered |